Shattuck Labs
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 W 5th St Ste 1200, Austin, Texas, 78...Phone Number
(512) 900-4690Website
www.shattucklabs.comRevenue
<$5 MillionStock Symbol
STTKIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
1
1
1
About Shattuck Labs
Shattuck Labs is a clinical-stage biotechnology company focused on research and development of innovative biologic medicines. Founded in 2016 and publicly traded on NASDAQ, the company specializes in developing bi-functional fusion proteins for treating cancer and autoimmune diseases. Shattuck's proprietary technology platforms include the Agonist Redirected Checkpoint (ARC) platform and the Gamma Delta T Cell Engager (GADLEN) platform, both designed to create novel therapeutic approaches. The company currently has multiple Phase 1 clinical trials underway for its product candidates. Headquartered in the United States, Shattuck maintains offices in both Austin, Texas and Durham, North Carolina, supporting its ongoing research and clinical development programs.Explore more
Shattuck Labs Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Shattuck Labs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Shattuck Labs has new funding data
Product Launch: Get notified when Shattuck Labs launches new products
Earning: See what the market has to say on Shattuck Labs recently announced quarterly report
Website visits: Recent activity has been detected on your website
Shattuck Labs, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Shattuck Labs has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Shattuck Labs
Click to see if Shattuck Labs had a recent Job posting/layoffs
Check out if Shattuck Labs is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Shattuck Labs
Compare insights from companies similar to Shattuck Labs, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Shattuck Labs is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Shattuck Labs is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Shattuck Labs.
Shattuck Labs financials insights
Gather financial insights about Shattuck Labs, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$7M
2020
Multiple Rounds
$345.4M
Shattuck Labs Tech Stack
A closer look at the technologies used by Shattuck Labs
Most Recent Scoops
Person-Based
Earnings, Clinical Operations, Finance
Person-Based
Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
Medical Research, Clinical Operations
Shattuck Labs News & Media
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals –Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
An analyst initiated coverage of the biotech with a buy recommendation.STTK Secures Financing with Offering Range Between $4.00 and $4. - GuruFocus
On June 10, 2026, Shattuck Labs Inc (STTK) announced that it has successfully set an offering price in the range of $4.00 to $4.25 per share. This financing iniShattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price pe
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Shattuck Labs
Sign Up For FreeTo access detailed company insights
Shattuck Labs is a clinical-stage biotechnology company focused on research and development of innovative biologic medicines. Founded in 2016 and publicly traded on NASDAQ, the company specializes in developing bi-functional fusion proteins for treating cancer and autoimmune diseases. Shattuck's proprietary technology platforms include the Agonist... Read More
